Literature DB >> 19845760

Fluorescence induction of protoporphyrin IX by a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness ex vivo skin model.

Tim Maisch, Francesco Santarelli, Stephan Schreml, Philipp Babilas, Rolf-Markus Szeimies.   

Abstract

An ex vivo porcine skin model was utilized to analyse the penetration of 5-aminolevulinic acid (5-ALA) contained in a nanoemulsion-based formulation BF-200 ALA (10% 5-ALA-hydrochloride) versus 16% aminolevulinate methyl ester-hydrochloride in a commercially cream (MAL cream) by fluorescence microscopy of their common metabolite protoporphyrin IX (PpIX) after 3, 5, 8 and 12 h. Fluorescence signals of PpIX in pig skin treated with BF-200 ALA were stronger than those for MAL cream. At 8 and 12 h, the PpIX fluorescence signals were 4.8- and 5.0-fold higher than those measured after MAL cream application. Fluorescence signals of PpIX after application of BF-200 ALA were detected in deeper tissue layers of the epidermis than after application of MAL cream (97.2 +/- 5.7 microm for BF-200 ALA vs 42.0 +/- 4.2 microm for MAL cream). These data implicate that BF-200 ALA in photodynamic therapy might lead to a superior therapeutically effect of intraepidermal (in situ) squamous cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19845760     DOI: 10.1111/j.1600-0625.2009.01001.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  11 in total

1.  Can nanotechnology potentiate photodynamic therapy?

Authors:  Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Hoon Chung; Anastasia Yaroslavsky; Maria Garcia-Diaz; Julie Chang; Long Y Chiang; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2012-03       Impact factor: 7.848

2.  δ-Aminolevulinic acid and its methyl ester induce the formation of Protoporphyrin IX in cultured sensory neurones.

Authors:  B Novak; R Schulten; H Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-25       Impact factor: 3.000

3.  Comparison of the uptake of 5-aminolevulinic acid and its methyl ester in keratinocytes and skin.

Authors:  R Schulten; B Novak; B Schmitz; H Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-17       Impact factor: 3.000

4.  Current Advances in 5-Aminolevulinic Acid Mediated Photodynamic Therapy.

Authors:  Connor Thunshelle; Rui Yin; Qiquan Chen; Michael R Hamblin
Journal:  Curr Dermatol Rep       Date:  2016-07-13

Review 5.  Photodynamic Therapy with 5-aminolevulinic Acid 10% Gel and Red Light for the Treatment of Actinic Keratosis, Nonmelanoma Skin Cancers, and Acne: Current Evidence and Best Practices.

Authors:  Nathalie C Zeitouni; Neal Bhatia; Roger I Ceilley; Joel L Cohen; James Q Del Rosso; Angela Y Moore; Gilly Munavalli; David M Pariser; Todd Schlesinger; Daniel M Siegel; Andrea Willey; Mitchel P Goldman
Journal:  J Clin Aesthet Dermatol       Date:  2021-10

Review 6.  Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.

Authors:  Demian van Straten; Vida Mashayekhi; Henriette S de Bruijn; Sabrina Oliveira; Dominic J Robinson
Journal:  Cancers (Basel)       Date:  2017-02-18       Impact factor: 6.639

7.  Clinical Pharmacokinetics and Safety of a 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel (BF-200 ALA) in Photodynamic Therapy of Patients Extensively Affected With Actinic Keratosis: Results of 2 Maximal Usage Pharmacokinetic Trials.

Authors:  Ben Novak; Janet DuBois; Osama Chahrour; Tamara Papusha; Stefan Hirt; Thomas Philippi; Corinna Zogel; Katharina Osenberg; Beate Schmitz; Hermann Lübbert
Journal:  Clin Pharmacol Drug Dev       Date:  2021-10-11

8.  Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin.

Authors:  Henriëtte S de Bruijn; Sander Brooks; Angélique van der Ploeg-van den Heuvel; Timo L M Ten Hagen; Ellen R M de Haas; Dominic J Robinson
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

9.  Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.

Authors:  Alison Curnow; Alexis Perry; Mark Wood
Journal:  Photodiagnosis Photodyn Ther       Date:  2018-12-13       Impact factor: 3.631

10.  Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis.

Authors:  T Dirschka; P Radny; R Dominicus; H Mensing; H Brüning; L Jenne; L Karl; M Sebastian; C Oster-Schmidt; W Klövekorn; U Reinhold; M Tanner; D Gröne; M Deichmann; M Simon; F Hübinger; G Hofbauer; G Krähn-Senftleben; F Borrosch; K Reich; C Berking; P Wolf; P Lehmann; M Moers-Carpi; H Hönigsmann; K Wernicke-Panten; S Hahn; G Pabst; D Voss; M Foguet; B Schmitz; H Lübbert; R-M Szeimies
Journal:  Br J Dermatol       Date:  2013-04       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.